Citius Oncology, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$110M
↑+21.5% +$19Mvs FY2024
Total Liabilities
$52M
↑+4.8% +$2Mvs FY2024
Equity
$58M
↑+41.5% +$17Mvs FY2024
Cash
$7M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $110M | $90M |
| Current Assets | $37M | $17M |
| Cash | $7M | $0 |
| ST Investments | $0 | $0 |
| Receivables | $4M | $0 |
| Inventory | $23M | $14M |
| Other Current | $3M | $3M |
| Non-Current Assets | $73M | $73M |
| PPE | $0 | $0 |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $73M | $73M |
| Total Liab+Eq | $110M | $90M |
| Current Liab. | $45M | $43M |
| Accounts Payable | $10M | $6M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $34M | $38M |
| Non-Current Liab. | $7M | $6M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $7M | $6M |
| Equity | $58M | $41M |
| Retained Earnings | $70M | $46M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · CTOR · Comparing FY2025 vs FY2024